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The  ability  to  make genetic changes  in  the mouse germline  in a 
predetermined way has  resulted from the combination of two tech- 
nologies developed during the past 10 years. The first of these 
technologies is  the mouse embryonic stem (ES)’ cell system. ES 
cells (1, 2) are derived from the  inner cell mass of a mouse blasto- 
cyst and  remain  undifferentiated  under  suitable  tissue  culture con- 
ditions. Yet when  these in  vitro cultured cells are introduced into a 
blastocyst for continuation of their development in  utero they  can 
yield mouse chimeras  able  to  transmit  the ES cell genome to  their 
offspring (3). Genetic changes introduced into ES cells in tissue 
culture  can  therefore b transferred  into live mice (4-6)  by breeding 
the  chimeras  and  screening offspring for the ES genotype (usually 
by coat color). The second technology, gene targeting,  uses homol- 
ogous recombination to  alter a chosen  gene in a predetermined way 
(7, 8).  Gene  targeting  in ES cells provides the capability of selec- 
tively altering genes in the mouse (9, 10). In what follows we 
consider various applications of this process. Our review does not 
attempt  to reference all  reported applications of gene  targeting  to 
alter  genes  in  animals  but  rather  to exemplify the major  categories 
of its usage. Other  recent reviews  include Refs. 11-16. 
Gene Disruptions 
The most frequent application of gene targeting is the “gene 
knockout,” an event  mediated by homologous recombination, re- 
sulting  in  the  disruption of a specific gene. There  are two main 
types of gene-targeting vectors, insertion  and  replacement,  with 
several design  options  available. Insertion  (0-type) vectors mediate 
a homologous recombination event  with a single crossover, during 
which the regions of homology are duplicated (see Fig. 1); this 
duplication of sequences is  essential for some types of gene target- 
ing, such  as  “hit  and run”/“in-out” and gene  duplication  (see below). 
Replacement (R-type) vectors are more commonly used for simple 
gene  disruptions (Fig. 1B).  The two regions of homology (the  arms 
of the R), preferably  designed to  eliminate some of the  target gene, 
are  generally  separated by a selectable marker gene  such as a neoR 
gene in  the loop of the R (S1 in Fig. 1 B ) .  
Vectors are  usually  transferred  to ES cells via electroporation, 
and cells that contain  the  targeting  construct  are identified by their 
survival  in  the presence of a drug  such as G418 (an aminoglycoside 
related  to neomycin). This  is  referred  to as positive selection. The 
fact  that most cells surviving  the S1 selection will have  integrated 
the  targeting vector randomly by non-homologous recombination 
into  the genome, rather  than at the  target locus by homologous 
recombination, led to the development of a negative selection 
scheme (17). Inclusion of another selectable marker (52 in Fig. 1 B )  
in  the  targeting vector just  outside one of the regions of homology 
allows for concomitant negative selection. The  herpes simplex thy- 
midine kinase (TK)  gene in conjunction with  the  drug ganciclovir 
has been  very  successful in  this context, as was originally  described 
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(17). Most of the cells taking  up  the  targeting vector randomly  into 
their genomes retain and express the TK gene; they are conse- 
quently killed by ganciclovir. In  the  much  smaller proportion of 
cells that  integrate  the vector by homologous recombination, the 
TK  gene is  lost  in  the homologous crossover event, allowing the 
targeted cells to  survive  in  the presence of ganciclovir. Despite this 
double enrichment for targeted cells, a DNA screening method is 
usually  required  to identify correctly targeted cells. When the  tar- 
geting frequency is high, the  screening  can  be done by Southern 
blot analysis.  In  less favorable  cases,  a  polymerase chain reaction- 
based  recombinant  fragment  assay is more efficient (18). 
Several  hundred different mutant mouse lines  have now been 
generated by the gene disruption mode of targeting  in ES cells. 
While most of the  disruptions  result  in a null allele, this is not 
always  the case.  Depending on the  details of the  targeting scheme, 
the  resulting mice may produce no functional gene product, a trun- 
cated product,  or an alternatively spliced product. There is a dif- 
ference in  the  severity of the phenotype  between mice unable t o  
synthesize  the cystic fibrosis transmembrane receptor  gene  product 
(19-21) and mice having a disrupted gene that can be alternatively 
spliced and  is consequently  “leaky”  (22).  Similarly, homozygotes for 
two different targeted  mutations  in  the N-myc gene result  in  either 
no detectable N-myc (23-25) or 25%  of normal levels of the  protein 
(26). The  null  mutation is lethal at embryonic  day 10.5; homozy- 
gotes for the  leaky  mutation display perinatal lethality. Compound 
heterozygotes of the  null  mutation  and  the  leaky  mutation  have 
N-myc levels  approximately 15% of normal  and  have a  correspond- 
ingly intermediate phenotype  (27). 
Not surprisingly, the phenotypes of mice with null mutations 
range from having  little effect on the  health  and viability of the 
mutant  animal  to being lethal  in  early embryonic life. An example 
of the former class  is  the mice resulting from inactivation of the 
gene coding for &-microglobulin, a protein  subunit of the major 
histocompatibility  class I molecules (28). These mice have only very 
low levels of class  I proteins on cell surfaces  and a virtual absence 
of CD8+ T-cells, which are  dependent on  class I proteins for their 
development in  the  thymus;  yet  the  animals  are  born  normal  and 
show no obvious phenotype. Despite the easily detectable alter- 
ations  in  the  immune  system, only when  the  animals were studied 
more extensively did it become apparent  that  the mice have  in- 
creased  susceptibility to a small  subset of infectious agents (29). In 
contrast,  disruption of the gene coding for GATA-1, an  erythroid- 
specific transcription factor, proved to be lethal  in  early  fetal de- 
velopment (30). In  such  cases of lethality, ES cells that  are homozy- 
gous or hemizygous for a given targeted  mutation  can be injected 
into blastocysts and  their  fate  can be determined.  In  this example, 
in  which, the gene for GATA-1 is X-linked and  the ES cells were 
male,  the hemizygous mutant ES cells contributed  to most tissues, 
but only cells of the wild-type host blastocyst  were  detected in  the 
erythroid  compartment of the  resulting chimeric  embryos. Thus, 
lack of the GATA-1 gene  product  precludes normal  erythroid devel- 
opment, although the mutant cells can contribute normally to 
many  other  tissues. 
In most cases a disrupted gene will be autosomal so that  the  use 
of chimeras  to  analyze severe mutations will be most  informative if 
the ES cells are first made homozygous for the  disruption.  This  has 
been achieved in two  ways.  One way is  to  use a hygromycin resist- 
ance gene as a selectable marker for targeted disruption of the 
second allele  (31,321. Another way of obtaining ES cells containing 
homozygous disruptions is by selecting cells that survive in  the 
presence of an increased concentration of G418; often  among the 
survivors are colonies that  have two copies of the neoR gene as a 
consequence of becoming homozygous for the  mutation (33, 34). 
Homozygous gene disruptions  in ES cells obtained by either 
method are  valuable  reagents for in  vitro studies  (see below) or for 
direct  injection into blastocysts. 
Gene Modifications 
While gene disruptions  demonstrate  the effect of the absence of 
gene  function during  normal development and  can model human 
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RG. 1. A represents  a  generic  insertion (0-type) targeting  event, 
and E represents a generic replacement (a-type) t eting event. 
The  following conventions are  shared by all figures. The e3ogenous chro- 
mosome and the  target locus are shown in blue and the targeting constructs 
in yellow or gray. Continuity with chromosomal DNA is indicated by vertical 
jagged lines. Plasmid sequences and selectable markers  are shown in black 
for 51, or against 82, does not influence the recombination event but allows 
and white. The resulting targeted locus is shown  below the arrow. Selection 
the selective survival of cells that have undergone the desired event. Note 
that  the crossovers (X) can  occur anywhere within the region of homology; 
the crossover points depicted are a rb i t rq .  
disorders caused by recessively inherited single gene  defects, they 
generally are not suitable for analyzing or modeling the effects of 
an altered gene  product. However,  homologous recombination  can 
be used to modify  gene products in a variety of increasingly sophis- 
ticated ways. In a simple  form the targeting construct is of the re- 
placement  type, having a positively selectable gene inserted either 
upstream of the promoter of the  target gene  or downstream of the 
poly(A) addition site. The  method has been  used in tissue culture to 
change the human sickle cell ps globin mutation to the normal PA 
form (35). The  method has also  been  used to create a single amino 
acid  change in the proopiomelanocortin  gene in ES cells (36). 
A colorful variation on this method  involves the insertion of the 
marker gene lac2 into the proto-oncogene int-2 by homologous 
recombination, creating an int-2-lac2 fusion  gene (37). The result- 
ing lac2 expression parallels the expression of wild-type int-2 in in 
vitro differentiated ES cells. This type of experiment is an effective 
way of observing the expression patterns of a particular gene and 
can also mark certain cell types for the study of  cell lineage in uiuo. 
Repeated Targeting at a Single Locus 
In many situations, it is desirable to study a series of changes in 
the structure of a target gene.  The  difficulty of obtaining multiple 
conventional targeting events has resulted in several schemes  for 
repeatedly targeting a locus (38-41). AU these schemes employ 
conventional  gene targeting to convert the target locus into a modi- 
fied  form,  which then allows a second targeting event to be carried 
out repeatedly with the help of a more  favorable system of selec- 
tion. Fig. 2 illustrates  the scheme  employed  by  Askew et al. (38) in 
their "tag and exchange" system and by Stacey et al. (39) and Wu et 
al. (40) in their "double replacement" system. The first  targeting 
step, which  need  only  be carried out once, uses conventional  gene 
targeting with  positive  selection  for S1 to introduce a negatively 
selectable marker gene 52 into or close to the target gene. The 
second targeting step, which is readily repeated with minor varia- 
tions, then uses negative selection against the function of 52 to 
obtain the altered locus.  Askew et al. (38) chose the neoR gene  for S1 
in conjunction with G418 selection and the herpes simplex virus TK 
gene  for 52 in conjunction with ganciclovir  selection. A potential 
drawback  when using the TK gene  for S2 is that males having a TK 
gene  expressed in their  testes are likely to be infertile (42). Conse- 
quently, it may be  difficult to test  the germline  competence of the 
tagged ES cells and to obtain useful animals before  completing step 
2. Instead of S1 and S2, Stacey et al. (39) used a single gene (a 
hypoxanthine phosphoribosyltransferase (HPRT)  minigene) in 
HPRT- ES cells in conjunction with hypoxanthine-aminopterin- 
thymidine (HAT) medium for the first  step positive  selection and 
used 6-thioguanine medium  for the second step negative selection. 
(When an HPRT  minigene is used the ES cells must be  HPRT-  (61.) 
Schemes of the type shown in Fig. 2 have the advantage that the 
final modified  locus  does  not retain any sequences derived  from S1 
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FIG. 2. The  incorporation of a  subtle  change ("E" to "e") and  the 
subsequent  removal of selective  sequences using a repeatable  tar- 
geting  scheme. The 6nal locus is the  result of two  consecutive targeting 
events, both of the replacement type. The first event (A), which is, a conven- 
tional targetin event that introduces 51 and S2 near  the  target gene, need 
not be repeatef The second targeting event ( B )  can be efficiently repeated to 
incorporate many different types of changes, all accompanied by removal of 
the selectable marker sequences. 
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FIG. 3. The  incorporation of a  subtle  change V"' to "e") using the 
recombination-dependent  positive selection in a repeatable  target- 
ing  scheme. The final locus is the  result of two  consecutive targeting events 
(A and B ) ,  both of the replacement The first conventional targeting 
event (A) introduces S1 and AS2 near% target gene. The second targeting 
event ( B )  can be efficiently repeated to incorporate many Merent t 
changes. Note that positive selection is used in this repeatable step anrh:: 
52 function is only generated by  homologous  recombination  allowing detec- 
tion of difficult targeting events. 
or S2 (see also  below). A potential disadvantage is that loss of S2 
gene  function  can occur in a variety of ways in addition to the gene 
loss  accompanying the desired second step recombination. Judging 
from the published numbers of non-targeted colonies  observed after 
the second step, this disadvantage is less important with the HPRT 
minigene than with the TK gene. This might be expected,  since 
positive  selection to ensure retention of HPRT gene function can be 
maintained right up to the time of the second electroporation. 
Fig. 3 illustrates a "plug and socket" system developed at  the 
University of North Carolina, which employs recombination-de- 
pendent positive  selection  for gain of function in both steps (41). 
The neoR gene in conjunction with G418 selection is used conven- 
tionally as S1 for the first  step. 52, in this case an HPRT  minigene, 
is divided into two individual non-functional but overlapping parts. 
One part, AS2 (the "socket") is non-functional  because it lacks the 
5' end of the HPRT  gene; it is on the first targeting vector and so is 
introduced near the target locus in  step one. The other part of the 
HPRT  minigene, S2A (the "plug") is non-functional  because it lacks 
the 3' end of the HPRT  gene; it is on the second targeting vector. 
Only  when these two recombine by  homologous recombination  be- 
tween their overlapping  portions is a complete functional 52 gene 
obtained, making the targeted cells  HAT-resistant.  Many different 
plugs  can be inserted into the same socket.  The chief advantage of 
the scheme is the power of this positive  selection  for ecombinants 
between S2A and AS2, neither of which can become functional 
without homologous recombination. This precludes background 
colonies due to non-homologous events, and as a result diiXcult 
second targeting events can be  achieved. Disadvantages are  that 
the gene 52 remains near the target locus at completion of the 
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in two steps. The first step (A) is a conventional insertion (0-type) targetin 
FIG. 4. Ahit-and-din-out targeting  event  that  changes "R" to "r" 
event that adds the sequence T M E T  to the endogenous  locus; targetes 
cells survive selection for S1. The second step ( B )  is an intrachromosomal 
recombinational event that can  occur spontaneously, although at  a  low  &e- 
suency; recombinant cells survive selection against S2. The substitution of 
r" for "R" results when  crossovera  occur as depicted  by the X. 
targeting, and constraints on the placement of the 52 gene  may 
restrict the types of change that can be  effected. 
Eliminating Selectable Marker Sequences 
The problem of modifying a target gene without leaving any of 
the selectable marker sequences in the locus has been  approached 
by Hasty et al. (43) in their "hit and run" scheme and by Valancius 
and Smithies (44) in  their "in and out"  scheme, both of which are 
illustrated  in Fig. 4. The  vector introduces the desired modification 
together with a negatively selectable gene S2 as a consequence of a 
conventional insertion (0-type) targeting event; this event is 
achieved with the help of positive  selection  for the marker gene 51. 
Note that (as in all insertion type events) the homologous se- 
quences are duplicated during this step. The  second event, which 
eliminates the selectable gene,  occurs as a consequence of a spon- 
taneous intrachromosomal (or sister chromatid) exchange  between 
the sequences that were duplicated during the first insertion event. 
Although spontaneous deletions of this type are infrequent events, 
selection against S2 function  allows their recovery. 
Hasty et al. (43) used the neoR gene for S1 and the TK gene for 
S2. Valancius and Smithies (44) used a single HPRT  minigene  for 
S1 and 52 with HAT medium  for the positive  selection and 6-thio- 
guanine-containing medium  for the negative selection. Either 
method  can be used to generate a wide range of mutations, from 
single base substitutions to the exchange or removal of large re- 
gions of regulatory or coding  sequences, without leaving any un- 
wanted sequences in the final modified  locus. 
Another method of eliminating selectable marker sequences 
takes advantage of a site-specific  recombinase system. Both the 
FLP recombinase system from yeast (45,461 and  the Cre-2ozP sys- 
tem from  bacteriophage P1 (47) have been demonstrated to func- 
tion in ES cells with similar applications. Targeting constructs for 
this type of application incorporate the necessary cis-acting se- 
quences so that they flank the selectable marker. f i r  conven- 
tional targeting of the locus by  homologous recombination, the ES 
cells are transfected with a vector expressing the recombinase. 
Cells that have undergone site-specific recombination and have 
therefore deleted the marker sequences can  be identified by South- 
ern analysis or polymerase chain reaction. In contrast to the "in 
and out" and "hit and run" strategies, the recombinase systems 
leave behind a single copy  of the recombination  sequences,  approxi- 
mately 50 base pairs  in length, but recombinase-mediated  excision 
of selectable marker sequences is very  efficient. 
It is important to remember that  the structure  and behavior of 
each individual locus, as well as the specific  genetic  modification 
that  is desired, will influence the type and design of the targeting 
vector; all methods are not suitable for all applications. Experi- 
ments involving  removal of Selectable marker sequence are more 
complicated than those in which the selectable marker remains. 





FIG. 5. The duplication of a locus via a gaprepair targeting 
yellow with 2 Z u e  lettering. The gap can be >I5 &lobases. 
scheme. Se uences generated as a result of re airing the gap are shown in 
Gene Duplications 
Complex genetic diseases, such as atherosclerosis and essential 
hypertension, have a mixed genetic and environmental etiology. 
Many genes contribute to the wide range of phenotypes  observed. A 
general method  for investigating in animals the effects of increasing 
the levels of a gene product without altering the nucleotide se- 
quence,  chromosomal  location, or regulatory elements of the gene of 
interest is likely to be  of great value in studying these complex dis- 
eases. Fig. 5 illustrates a "gap-repair" targeting scheme that gen- 
erates a tandem duplication of a gene, thereby allowing the pro- 
duction of animals with three or four  gene  copies.  The targeting 
constmct is an insertion (0-type) vector that uses positive  selection 
(91) and negative selection (52) to accomplish the targeted gene 
duplication. Several features of the targeting construct are impor- 
tant. The construct must include two  regions of  homology,  one from 
upstream (5') and one  from downstream (3') of the  target locus. (TA 
and ET represent these sequences in Fig. 5.) In order to maximize 
the probability that both  copies of the tandemly duplicated gene will 
be functional, TA and ET must extend far enough upstream and 
downstream of the  target gene so that all known regulatory se- 
quences  lie  between their respective 5' and 3' ends. Because  double 
strand gap repair can  fill in a gap during an  0-type targeting event 
(48, 491, the construct can include a large gap and so can be  con- 
siderably shorter  in length than  the gene that is to be duplicated. 
A duplicated gene can mimic up-regulation of an endogenous 
gene, allowing the effects of an increase in gene product to be 
investigated. Duplicated  genes,  produced by gap-repair, have a dis- 
tinct advantage over randomly integrated transgenes in that they 
are created at the original  locus.  Consequently they are expected to 
share  the same chromosomal  effects (heterochromatization, methyl- 
ation, DNase hypersensitivity, etc.) as  the normal gene.  Compari- 
son of mice  from a line carrying a duplication of a gene of interest 
with mice from a line carrying a disruption of the same gene  allows 
one to observe animals having from  zero to four copies of the de- 
sired gene.  Application of this scheme to the gene coding  for  angio- 
tensinogen has resulted in first generation (F1) animals with 
steady state plasma angiotensinogen levels ranging from 35% (1 
gene copy) to 124% (3 gene  copies) of normal  levels (50). The second 
generation (F2) animals provide  zero and four copy animals having 
no plasma angiotensinogen and 148% of normal levels? 
Single-copy, Single-position  mansgenes 
A tremendous amount of valuable information has come  from 
studies of transgenic animals made by injecting DNA into the pro- 
nucleus of fertilized eggs (for review see Ref. 51). However, in any 
situation where  exogenous DNA is integrated randomly into the 
genome, there are three potential problems: insertion of the  trans- 
gene into an essential gene, variable transcription of the transgene 
due to position  effect, and unpredictable copy number. Targeting of 
transgenic sequences to a specific  locus  by  homologous recombina- 
tion in  ES cells  avoids these three hazards and facilitates the pro- 
duction of many different types of transgenes. 
The  HPRT  locus is a very useful locus  for such targeted trans- 
genes and can take advantage of the partially deleted HPRT  locus 
available in the E14TG2a ES cell line (6).  The junction sequences of 
the partial deletion are well characterized and have been used 
previously to create an &type targeting vector  (52). This vector has 
5' and 3' homology fragments from 5' and 3' of the deletion break- 
point, respectively.  The central portion of the targeting construct is 
arranged to contain both the missing portion of the HPRT  gene and 
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the coding and  regulatory sequences of the desired transgene.  In- 
troduction of sequences complementary to the deletion restores 
function to  the HPRT  gene; homologous recombination events at 
the locus can therefore be directly selected in HAT media. The 
overall result  is  the  insertion of a single copy of the  transgene  into 
the HPRT locus. Several different regulatory  and coding sequences 
have been inserted  into  the HPRT locus using  this method and lead 
to  moderate levels of promoter-specific transcription  in  the  result- 
ing mice.3 Study of the effect of changing  the promoters is  then 
possible free from the complications of position effects and  variable 
copy numbers. 
Advantages of ES Cells 
The major advantages of using ES cells for genetic modifications 
are  that  they  are  easy  to  culture,  are readily manipulated by ho- 
mologous recombination in  vitro, are  amenable  to a wide variety of 
selection and  screening schemes to  detect relatively rare homolo- 
gous recombination events, and can be used to make genetic 
changes  in  the mouse. They  have  several  other  advantages. For 
example, chimeras generated by the injection of ES cells into 
blastocysts provide an elegant way of directly  comparing the  fate 
of modified cells and wild-type cells in different cell lineages. 
Hermiston et al. (53) have  demonstrated  the  use of such  animals  in 
the  analysis of intestinal  epithelial cell lineages. Intestinal  crypts 
are derived from the differentiation of single cells in  the  intestinal 
mucosa, and cells derived from wild-type and  mutant cell lineages 
of a  chimeric animal  can be observed in  adjacent crypts.  Similarly, 
modified ES cells can be injected into blastocysts  derived from a 
genetically modified mouse line allowing  direct in  vivo comparison 
of two different mutant  lineages, as in  the RAG-2-deficient blasto- 
cyst complementation assay described by Chen et al. (54). (The 
RAG-2-deficient blastocysts  provide  a B- and T-cell negative  back- 
ground  against which lymphoid-specific modifications can be 
analyzed.) 
Another  important  feature of ES cells is  their  ability  to differen- 
tiate  into a variety of tissue  types in  vitro via the formation of 
embryoid bodies (55). All three  germ  layers  have been observed, 
and  several different types of cells can be derived from embryoid 
bodies, including  hematopoietic cells, nerve cells, myocardium, and 
cartilage (56). It  seems likely that  further knowledge of the role of 
various  culture components in  determining  the fficiency and spec- 
ificity of differentiation of ES cells into specialized tissues will 
result  in a number of very valuable  assay  systems  in which the 
wide variety of targeted modifications achievable in  these cells can 
be evaluated in  vitro, alleviating  the need to go through  the com- 
plex steps  necessary  to  generate an animal. 
Conclusion 
Manipulation of the mouse germline  through  the genetic modi- 
fication of embryonic stem cells is clearly a very useful and ex- 
tremely  versatile tool for analyzing  mammalian development and 
physiology and for creating models of human diseases. In  addition 
to  the widely utilized  method of gene disruption, homologous re- 
combination can mediate many other types of genetic changes, 
including both  qualitative  and  quantitative modifications, making 
i t  practical to  analyze  the effects of many  types of genetic  changes 
on complex traits.  The  versatility of genetically modified ES cells is 
facilitating  the  rapid expansion of a  very  informative pool of in- 
duced mutations  in mice and  is allowing important  questions  to be 
addressed in  vivo regarding gene  expression and  protein function 
and  their  impact on normal  and  disease  states. 
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